Teva Announces New Olanzapine LAI (TEV-‘749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adultsfinancialpost.com2d agoRead at financialpost.comEarlier from this sourceMISSION SUCCESS: Rocket Lab Launches 96th Electron Mission1d agoCollective Metals Announces Management Changes2d agoLiberty Gold Files Feasibility Study Technical Report for the Black Pine Project in Idaho, USA2d agoAjax library workers reject two-tier contract: ‘We need a fair deal for everyone’2d agoGreenland Mines Applauds Historic U.S.-Denmark-Greenland Security Agreement, Reinforcing Greenland’s Strategic Importance to the United States2d agoOttawa’s ‘mega deduction’ tax write-off could boost these TSX stocks, analysts say2d agoNews of the day: The antagonist next door, variable-rate’s moment, how high will interest rates go, workplace investigations, dual-citizen taxes and more2d agoPIMCO Canada Corp. Announces Monthly Distributions for PIMCO Canada Closed End Funds2d agoHow this page changedShareSign in to saveLink